Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220686
Title: Interspecies transcriptomic comparison identifies a potential porto-sinusoidal vascular disorder rat model suitable for in vivo drug testing.
Author: Campreciós Figueras, Genís
Vilaseca Barceló, Marina
Tripathi, Dinesh
Montironi, Carla
Díaz, Alba
Aguilar, Daniel
García Calderó, Héctor
Montañés, Rosa
Anton, Aina
Hernández Gea, Virginia
García Pagán, Juan Carlos
Keywords: Malalties del fetge
Malalties vasculars
Models animals en la investigació
Liver diseases
Vascular diseases
Animal models in research
Issue Date: Jan-2024
Publisher: John Wiley & Sons
Abstract: Background: Porto-sinusoidal vascular disorder (PSVD) involves a group of rare vascular liver diseases of unknown aetiology that may lead to the development of portal hypertension and its life-threatening complications. Its pathophysiology is not well understood, and animal models described to date do not fully recapitulate human disease. Methods: We developed three different PSVD rat models by either immunosensitization (repetitive intraportal LPS or intramuscular spleen extract injections) or toxic (Selfox: combination of FOLFOX and a selenium-enriched diet) treatment and characterized them at haemodynamic, histological, biochemical and transcriptional levels. We compared these results to human data. Results: All three models developed significant portal hypertension, while only the LPS and the Selfox models displayed PSVD-specific and nonspecific histological alterations in the absence of cirrhosis. Transcriptional comparison between rat models and human data showed that both LPS and Selfox models recapitulate the main transcriptional alterations observed in humans, especially regarding haemostasis, oxidative phosphorylation and cell cycle regulation. Reproducibility and feasibility was higher for the Selfox model. Conclusions: The Selfox rat model faithfully reproduces the main alterations described in PSVD. Its use as a preclinical model for drug testing in progressing PSVD can be a significant step forward towards the development of new therapeutic targets for this rare condition.
Note: Reproducció del document publicat a: https://doi.org/10.1111/liv.15765
It is part of: Liver International, 2024, vol. 44, num.1, p. 180-190
URI: https://hdl.handle.net/2445/220686
Related resource: https://doi.org/10.1111/liv.15765
ISSN: 1478-3223
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
861708.pdf36.87 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons